BRTX
Income statement / Annual
Last year (2025), BioRestorative Therapies Inc's total revenue was $359.70 K,
a decrease of 10.30% from the previous year.
In 2025, BioRestorative Therapies Inc's net income was -$14.24 M.
See BioRestorative Therapies Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$359.70 K |
$401.00 K |
$145.80 K |
$119.80 K |
$46.00 K |
$77.00 K |
$130.00 K |
$111.00 K |
$81.00 K |
$36.36 K |
| Cost of Revenue |
$23.84 K
|
$28.07 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$259.26 K
|
$102.00
|
| Gross Profit |
$335.86 K
|
$372.93 K
|
$145.80 K
|
$119.80 K
|
$46.00 K
|
$77.00 K
|
$130.00 K
|
$111.00 K
|
-$178.26 K
|
$36.25 K
|
| Gross Profit Ratio |
0.93
|
0.93
|
1
|
1
|
1
|
1
|
1
|
1
|
-2.2
|
1
|
| Research and Development Expenses |
$10.09 M
|
$5.35 M
|
$4.03 M
|
$3.51 M
|
$729.06 K
|
$876.83 K
|
$1.72 M
|
$1.51 M
|
$2.15 M
|
$2.88 M
|
| General & Administrative Expenses |
$5.89 M
|
$6.58 M
|
$11.33 M
|
$15.58 M
|
$25.47 M
|
$1.92 M
|
$6.52 M
|
$5.89 M
|
$6.24 M
|
$4.86 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$158.37 K
|
$28.28 K
|
$321.28 K
|
$352.20 K
|
$65.46 K
|
$86.45 K
|
| Selling, General & Administrative Expenses |
$5.89 M
|
$6.58 M
|
$11.33 M
|
$15.58 M
|
$25.62 M
|
$1.95 M
|
$6.84 M
|
$6.25 M
|
$6.30 M
|
$4.95 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$59.94 K
|
-$46.61 K
|
| Operating Expenses |
$15.98 M
|
$11.93 M
|
$15.37 M
|
$19.09 M
|
$26.35 M
|
$2.83 M
|
$8.56 M
|
$7.76 M
|
$8.46 M
|
$7.83 M
|
| Cost And Expenses |
$16.01 M
|
$11.96 M
|
$15.37 M
|
$19.09 M
|
$26.35 M
|
$2.83 M
|
$8.56 M
|
$7.76 M
|
$8.46 M
|
$7.83 M
|
| Interest Income |
$266.21 K
|
$616.08 K
|
$552.29 K
|
$11.65 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.82 M
|
$1.64 M
|
$5.14 M
|
$3.22 M
|
$1.09 M
|
$763.94 K
|
| Depreciation & Amortization |
$209.99 K
|
$189.06 K
|
$165.74 K
|
$120.55 K
|
$89.11 K
|
$151.96 K
|
$217.45 K
|
$240.37 K
|
$259.26 K
|
$258.43 K
|
| EBITDA |
-$15.44 M |
-$11.37 M |
-$14.97 M |
-$18.74 M |
-$26.22 M |
-$9.48 M |
-$9.29 M |
-$9.06 M |
-$8.10 M |
-$7.61 M |
| EBITDA Ratio |
-42.92
|
-28.34
|
-102.69
|
-156.45
|
-569.97
|
-123.12
|
-71.47
|
-81.58
|
-99.98
|
-209.43
|
| Operating Income Ratio |
-43.5
|
-28.82
|
-104.39
|
-158.38
|
-571.91
|
-35.74
|
-64.86
|
-68.9
|
-103.39
|
-214.48
|
| Total Other Income/Expenses Net |
$1.41 M
|
$2.58 M
|
$4.80 M
|
$5.75 M
|
-$18.00 M
|
-$8.52 M
|
-$6.22 M
|
-$4.87 M
|
-$1.07 M
|
-$839.04 K
|
| Income Before Tax |
-$14.24 M
|
-$8.98 M
|
-$10.42 M
|
-$13.22 M
|
-$44.30 M
|
-$11.27 M
|
-$14.65 M
|
-$12.52 M
|
-$9.44 M
|
-$8.64 M
|
| Income Before Tax Ratio |
-39.59
|
-22.39
|
-71.45
|
-110.37
|
-963.12
|
-146.4
|
-112.68
|
-112.77
|
-116.6
|
-237.55
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$14.24 M
|
-$8.98 M
|
-$10.42 M
|
-$13.22 M
|
-$44.30 M
|
-$11.27 M
|
-$14.65 M
|
-$12.52 M
|
-$9.44 M
|
-$8.64 M
|
| Net Income Ratio |
-39.59
|
-22.39
|
-71.45
|
-110.37
|
-963.12
|
-146.4
|
-112.68
|
-112.77
|
-116.6
|
-237.55
|
| EPS |
-1.58 |
-1.16 |
-2.47 |
-3.65 |
-37.3 |
-28.56 |
-3217.82 |
-4269.37 |
-6181.06 |
-7356.3 |
| EPS Diluted |
-1.58 |
-1.16 |
-2.47 |
-3.65 |
-37.3 |
-28.56 |
-3217.82 |
-4269.37 |
-6181.06 |
-7356.3 |
| Weighted Average Shares Out |
$8.99 M
|
$7.76 M
|
$4.22 M
|
$3.62 M
|
$1.19 M
|
$394.70 K
|
$5.57 K
|
$2.93 K
|
$1.53 K
|
$1.17 K
|
| Weighted Average Shares Out Diluted |
$8.99 M
|
$7.76 M
|
$4.22 M
|
$3.62 M
|
$1.19 M
|
$394.70 K
|
$5.57 K
|
$2.93 K
|
$1.53 K
|
$1.17 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
